½ÃÀ庸°í¼­
»óǰÄÚµå
1347909

ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå : ¼Ö·ç¼Ç À¯Çü, ¹èÆ÷ ÇüÅÂ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(-2030³â)

Pharmaceutical Quality Management Systems Market by Solution Type, Deployment Mode, and End User - Global Forecast to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Meticulous Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 215 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå : ¼Ö·ç¼Ç À¯Çüº°(ÆíÂ÷, CAPA, °¨»ç, À§Çè ¹× ±ÔÁ¤ Áؼö, °Ë»ç, ¹®¼­, º¯°æ, ±³À° °ü¸®), ¹èÆ÷ Çüź°(Ŭ¶ó¿ìµå, ¿ÂÇÁ·¹¹Ì½º), ÃÖÁ¾»ç¿ëÀÚº°(Á¦¾à, CDMO/CRO) - ¼¼°è ¿¹Ãø(-2030³â)

ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö CAGR 15.6%·Î 2030³â±îÁö 39¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ 2Â÷ ¹× 1Â÷ Á¶»ç, ½ÃÀå ½Ã³ª¸®¿À¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ºÐ¼®À» ÅëÇØ ÁÖ¿ä »ê¾÷ÀÇ ¼ºÀå µ¿ÀÎ, ÀúÇØ¿äÀÎ, °úÁ¦, ±âȸ¸¦ Á¶»çÇß½À´Ï´Ù. Á¦¾à Á¦Á¶ ºñ¿ëÀÇ Áõ°¡, ±ÔÁ¦ ¿ä°Ç ÃæÁ·¿¡ ´ëÇÑ Á¦¾à ±â¾÷ÀÇ ¿ä±¸ Áõ°¡, Á¦¾à »ê¾÷ÀÇ ±Þ¼ÓÇÑ ¼ºÀå, ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ǰÁú °ü¸® ½Ã½ºÅÛÀÇ ÀåÁ¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦³×¸¯ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ¼ºÀå°ú Á¦¾à ±â¾÷ÀÇ ¼­ºñ½ºÇü Ç÷§Æû(Platform-as-a-Service) ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ½ÃÀåÀÇ ±â¾÷µé¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ³ôÀº ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ±¸Ãà ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à ±â¾÷ÀÇ ¿Â-Ŭ¶ó¿ìµå ±¸Ãà°ú °ü·ÃµÈ º¸¾È ¹®Á¦´Â ½ÃÀå ¼ºÀå¿¡ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

  • °³¿ä
  • ½ÃÀå ¼ºÀå ¿äÀÎ
    • ½ÃÀå ¿ªÇÐ
      • Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ±ÔÁ¦ ¿ä°Ç¿¡ ´ëÇÑ ´ëÀÀ ¿ä±¸ »ó½ÂÀÌ ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ Ã¤¿ëÀ» ÃËÁø
      • ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ µµÀÔÀÇ °íºñ¿ëÀÌ Ã¤¿ëÀ» Á¦ÇÑ
      • Á¦³×¸¯ ÀǾàǰ°ú ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå ¼ºÀå¿¡ ÀÇÇÑ ½ÃÀå ±â¾÷ ¼ºÀå ±âȸ âÃâ
      • ÀǾàǰ QMSÀÇ µµÀÔ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿ÂŬ¶ó¿ìµå µµÀÔ °ü·Ã º¸¾È»ó ¿ì·Á
    • ¿äÀÎ ºÐ¼®
  • µ¿Çâ
    • ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ¿¡ÀÇ ÀΰøÁö´É°ú ¸Ó½Å·¯´× ÅëÇÕ
    • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁöÇâ »ó½Â
  • ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå ±ÔÁ¦ ºÐ¼®
    • °³¿ä
    • ±¹Á¦ Ç¥ÁØÈ­ ±â±¸(ISO)
    • ÀǾàǰ »çÂû Çù·Â ½ºÅ´(PIC/S)
    • ICH °¡À̵å¶óÀÎ Q10
    • ÇöÇà ÀûÁ¤ Á¦Á¶ ±âÁØ(cGMP)
  • °¡°Ý ºÐ¼®
  • »ç·Ê ¿¬±¸

Á¦5Àå ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå : ¼Ö·ç¼Ç À¯Çüº° Æò°¡

  • °³¿ä
  • ºÎÀûÇÕ/ÀÏÅ» °ü¸®
  • ¹®¼­ °ü¸®
  • CAPA °ü¸®
  • ¸®½ºÅ©¡¤ÄÄÇöóÀ̾𽺠°ü¸®
  • °Ë»ç °ü¸®
  • °¨»ç °ü¸®
  • °ø±Þ¾÷ü¿Í ÀÚÀç °ü¸®
  • Æ®·¹ÀÌ´× °ü¸®
  • º¯°æ °ü¸®
  • ±âŸ ¼Ö·ç¼Ç À¯Çü

Á¦6Àå ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå Æò°¡ : µµÀÔ Çüź°

  • °³¿ä
  • Ŭ¶ó¿ìµå/À¥ ±â¹Ý
  • ¿ÂÇÁ·¹¹Ì½º

Á¦7Àå ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå Æò°¡ : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • °³¹ß¡¤Á¦Á¶¼öʱâ°ü/¿¬±¸ ¼öŹ ±â°ü
  • ¿¬±¸±â°ü

Á¦8Àå ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå Æò°¡ : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
  • º´¿ø¡¤Å¬¸®´Ð
  • Áø´Ü ¿¬±¸¼Ò
  • ÀçÅà ÇコÄɾî
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ÀǾàǰ ǰÁú °ü¸® ½Ã½ºÅÛ ½ÃÀå Æò°¡ : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¾ÆÀÏ·£µå
    • º§±â¿¡
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • ½Ì°¡Æ÷¸£
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • º£Æ®³²
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ºÐ¼®

  • °³¿ä
  • ÁÖ¿ä ¼ºÀå Àü·«
  • °æÀï º¥Ä¡¸¶Å·
  • °æÀï ´ë½Ãº¸µå
    • ¾÷°è ¸®´õ
    • ½ÃÀå Â÷º°È­ ¿äÀÎ
    • ¼±Çà ±â¾÷
    • ½ÅÈï ±â¾÷
  • ½ÃÀå ±â¾÷ ¼øÀ§(2022³â)

Á¦11Àå ±â¾÷ °³¿ä

  • Honeywell International Inc.
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç¡¤Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
    • SWOT ºÐ¼®
  • IQVIA Holdings Inc.
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • SWOT ºÐ¼®
  • Dassault Systemes SE
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
    • SWOT ºÐ¼®
  • Korber AG
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
    • SWOT ºÐ¼®
  • ANTARES VISION S.p.A.
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
    • SWOT ºÐ¼®
  • EtQ Management Consultants Inc.(A Subsidiary of Hexagon AB)
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
  • Ideagen PLC(A Subsidiary of Rainforest Bidco Limited)
    • ±â¾÷ °³¿ä
    • À繫 °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
  • AssurX, Inc.
    • ±â¾÷ °³¿ä
    • ¼Ö·ç¼Ç¡¤Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³
  • AXSource Consulting, Inc.
    • ±â¾÷ °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû °³¹ß
  • ComplianceQuest, Inc.
    • ±â¾÷ °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû °³¹ß
  • LogicGate, Inc.
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À
    • Àü·«Àû °³¹ß
  • MasterControl Solutions Inc.
    • ±â¾÷ °³¿ä
    • ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À
    • Àü·«Àû Àü°³

(ÁÖ : »óÀ§ 5°³»ç SWOT ºÐ¼®À» Á¦°ø ¿¹Á¤)

Á¦12Àå ºÎ·Ï

ksm 23.10.17

Pharmaceutical Quality Management Systems Market By Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management), Deployment Mode (Cloud, On-premise), and End User (Pharmaceutical, CDMO/CRO)-Global Forecast to 2030

The pharmaceutical quality management systems market is expected to reach $3.97 billion by 2030, at a CAGR of 15.6% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the increasing costs of drug manufacturing, pharmaceutical companies growing need to comply with regulatory requirements, the rapid growth of the pharmaceutical industry, and the benefits of software-based quality management systems. Additionally, the growing generic drugs & and biopharmaceuticals markets and pharmaceutical companies' increasing preference for platform-as-a-service solutions are expected to generate growth opportunities for the players in this market. However, the high costs of deploying pharmaceutical quality management systems restrain the growth of this market. Security concerns related to on-cloud deployments among pharmaceutical organizations are a major challenge for market growth.

Based on solution type, the pharmaceutical quality management systems market is segmented into non-conformance/deviation management, CAPA management, audit management, risk & compliance management, suppliers & materials management, inspection management, document management, change management, training management, and other solution types. The CAPA management segment is expected to grow at the highest CAGR during the forecast period. The need for Corrective and Preventive Action (CAPA) management in the pharmaceutical industry is driven by several factors that ensure product quality, patient safety, and regulatory compliance. CAPA management is essential for addressing issues and preventing their recurrence, further contributing to the overall integrity of pharmaceutical operations.

Based on deployment mode, the global pharmaceutical quality management systems market is segmented into cloud/web-based and on-premise. In 2023, the cloud/web-based segment is expected to account for the largest share of the pharmaceutical quality management systems market. The largest share of this segment is attributed to several advantages offered by cloud/web-based deployments over on-premise deployments, such as cost minimization, easy accessibility, adjustability, and updated cloud systems. Another major advantage of web-based deployments is the lower risk of data loss through better encryption and data backup.

Based on end user, the global pharmaceutical quality management systems market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations/contract research organizations, and research laboratories. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to increasing R&D investments by pharmaceutical & biotechnology companies, widespread utilization of quality management systems to ensure product quality, and a growing emphasis on personalized medicine research.

An in-depth analysis of the geographical scenario of the pharmaceutical quality management systems market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register with the highest CAGR during the forecast period. The healthcare needs of people in Asia-Pacific countries are progressively increasing due to the rising burden of chronic diseases. A large population pool and government initiatives to improve healthcare facilities and services in these countries are the key factors supporting the growth of the Asia-Pacific market. These countries have also been identified as low-cost destinations for pharmaceutical manufacturers for a long time, which further supports the growth of this market in Asia-Pacific.

Some of the key players operating in the global pharmaceutical quality management systems market are Honeywell International Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ANTARES VISION S.p.A (Italy), Dassault Systemes SE (France), EtQ Management Consultants, Inc. (U.S.), Ideagen PLC (U.K.), Korber AG (Germany), LogicGate, Inc. (U.S.), ComplianceQuest, Inc (U.S.), AssurX, Inc. (U.S.), and AXSource Consulting, Inc. (U.S.).

Scope of the Report:

Pharmaceutical Quality Management Systems Market Assessment by Solution Type

  • Non-conformance/Deviation management
  • Document Management
  • CAPA Management
  • Risk & Compliance Management
  • Inspection Management
  • Audit Management
  • Suppliers & Materials Management
  • Training Management
  • Change Management
  • Other Solution Types

(Other solution types include complaint management, out-of-specification, release management, incidents & and occurrence management, post-market surveillance, design control, and asset management.)

Pharmaceutical Quality Management Systems Market Assessment, by Deployment Mode

  • Cloud/Web-based
  • On-Premise

Pharmaceutical Quality Management Systems Market Assessment, by End User

  • Pharmaceutical and Biotechnology Companies
  • CDMO/CRO
  • Research Laboratories

Pharmaceutical Quality Management Systems Market Assessment, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Ireland
    • Belgium
    • Netherlands
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Singapore
    • Malaysia
    • Philippines
    • Vietnam
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for this Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Pharmaceutical Companies' Growing Need to Comply with Regulatory Requirements Driving the Adoption of Pharmaceutical Quality Management Systems
      • 4.2.1.2. High Costs of Deploying Pharmaceutical Quality Management Systems Limiting their Adoption
      • 4.2.1.3. Growing Generic Drugs & Biopharmaceuticals Markets Generating Growth Opportunities for Market Players
      • 4.2.1.4. Security Concerns Related to On-cloud Deployments Impacting the Implementation of Pharmaceutical QMS
    • 4.2.2. Factor Analysis
  • 4.3. Trends
    • 4.3.1. Integration Of Artificial Intelligence & Machine Learning into Pharmaceutical Quality Management Systems
    • 4.3.2. Increasing Inclination Toward Personalized Medicine
  • 4.4. Pharmaceutical Quality Management Systems Market: Regulatory Analysis
    • 4.4.1. Overview
    • 4.4.2. International Organization for Standardization (ISO)
    • 4.4.3. Pharmaceutical Inspection Co-Operation Scheme (PIC/S)
    • 4.4.4. ICH Guideline Q10
    • 4.4.5. Current Good Manufacturing Practice (cGMP)
  • 4.5. Pricing Analysis
  • 4.6. Case Studies

5. Pharmaceutical Quality Management Systems Market Assessment-by Solution Type

  • 5.1. Overview
  • 5.2. Non-Conformance/Deviation Management
  • 5.3. Document Management
  • 5.4. CAPA Management
  • 5.5. Risk & Compliance Management
  • 5.6. Inspection Management
  • 5.7. Audit Management
  • 5.8. Suppliers & Materials Management
  • 5.9. Training Management
  • 5.10. Change Management
  • 5.11. Other Solution Types

6. Pharmaceutical Quality Management Systems Market Assessment-by Deployment Mode

  • 6.1. Overview
  • 6.2. Cloud/Web-based
  • 6.3. On Premise

7. Pharmaceutical Quality Management Systems Market Assessment-by End User

  • 7.1. Overview
  • 7.2. Pharmaceutical And Biotechnology Companies
  • 7.3. Contract Development and Manufacturing Organization/ Contract Research Organization
  • 7.4. Research Laboratories

8. Pharmaceutical Quality Management Systems Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Hospitals & Clinics
  • 8.3. Diagnostic Laboratories
  • 8.4. Home Healthcare
  • 8.5. Other End Users

9. Pharmaceutical Quality Management Systems Market Assessment-by Geography

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Ireland
    • 9.3.7. Belgium
    • 9.3.8. Netherlands
    • 9.3.9. Rest of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
    • 9.4.4. Singapore
    • 9.4.5. Malaysia
    • 9.4.6. Philippines
    • 9.4.7. Vietnam
    • 9.4.8. Rest of Asia-Pacific
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Players Ranking (2022)

11. Company Profiles

  • 11.1. Honeywell International Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Overview
    • 11.1.3. Solution Portfolio
    • 11.1.4. Strategic Developments
    • 11.1.5. SWOT Analysis
  • 11.2. IQVIA Holdings Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Overview
    • 11.2.3. Solution Portfolio
    • 11.2.4. SWOT Analysis
  • 11.3. Dassault Systemes SE
    • 11.3.1. Company Overview
    • 11.3.2. Financial Overview
    • 11.3.3. Solution Portfolio
    • 11.3.4. Strategic Developments
    • 11.3.5. SWOT Analysis
  • 11.4. Korber AG
    • 11.4.1. Company Overview
    • 11.4.2. Financial Overview
    • 11.4.3. Solution Portfolio
    • 11.4.4. Strategic Developments
    • 11.4.5. SWOT Analysis
  • 11.5. ANTARES VISION S.p.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Overview
    • 11.5.3. Solution Portfolio
    • 11.5.4. Strategic Developments
    • 11.5.5. SWOT Analysis
  • 11.6. EtQ Management Consultants Inc. (A Subsidiary of Hexagon AB)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Overview
    • 11.6.3. Solution Portfolio
  • 11.7. Ideagen PLC (A Subsidiary of Rainforest Bidco Limited)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Overview
    • 11.7.3. Solution Portfolio
    • 11.7.4. Strategic Developments
  • 11.8. AssurX, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Solution Portfolio
    • 11.8.3. Strategic Developments
  • 11.9. AXSource Consulting, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Solution Portfolio
    • 11.9.3. Strategic Developments
  • 11.10. ComplianceQuest, Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Solutions Portfolio
    • 11.10.3. Strategic Developments
  • 11.11. LogicGate, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Product Portfolio
    • 11.11.3. Strategic Developments
  • 11.12. MasterControl Solutions Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Solution Portfolio
    • 11.12.3. Strategic Developments

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦